Catalyst Pharmaceuticals, Inc.(CPRX)Earnings, Financials & Key Ratios

CPRX•NASDAQ

$30.52

$3.74B mkt cap·18.2× P/E·Price updated May 6, 2026

SectorHealthcare IndustryBiotechnology Sub-IndustryCommercial Rare Disease Biopharma

AboutCatalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.Show more

Revenue$589M+19.8%
EBITDA$295M+26.8%
Net Income$214M+30.8%
EPS (Diluted)1.68+28.2%
Gross Margin85.19%-0.9%
EBITDA Margin50.13%+5.8%
Operating Margin43.77%+10.3%
Net Margin36.39%+9.2%
ROE25.49%-13.3%
ROIC83.93%+33.9%
Debt/Equity0.00-43.8%

Technical→

CPRX Key Insights

Catalyst Pharmaceuticals, Inc. (CPRX) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Company is almost debt free
✓Excellent 3Y average ROE of 25.2%
✓Strong 5Y profit CAGR of 23.4%
✓FCF machine: 35.4% free cash flow margin
✓Momentum leader: RS Rating 82 (top 18%)
✓Strong 5Y sales CAGR of 37.7%

✗Weaknesses

No significant weaknesses identified

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

CPRX Price & Volume

Catalyst Pharmaceuticals, Inc. (CPRX) stock price & volume — 10-year historical chart

Loading chart...

CPRX Growth Metrics

Catalyst Pharmaceuticals, Inc. (CPRX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years37.68%

3 Years40.1%

TTM19.78%

Profit CAGR

10 Years-

5 Years23.37%

3 Years37.15%

TTM30.78%

EPS CAGR

10 Years-

5 Years18.8%

3 Years30.84%

TTM28.24%

Return on Capital

10 Years10.9%

5 Years31.14%

3 Years29.88%

Last Year30.55%

CPRX Recent Earnings

Catalyst Pharmaceuticals, Inc. (CPRX) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 10/12 qtrs (83%)●Beat Revenue 7/12 qtrs (58%)

Q1 2026Latest

Feb 25, 2026

EPS

$0.68

Est $0.42

+61.9%

Revenue

$153M

Est $143M

+6.8%

Q4 2025

Nov 5, 2025

EPS

$0.68

Est $0.51

+33.3%

Revenue

$148M

Est $143M

+4.0%

Q3 2025

Aug 6, 2025

EPS

$0.68

Est $0.58

+17.2%

Revenue

$147M

Est $140M

+4.4%

Q2 2025

May 7, 2025

EPS

$0.68

Est $0.53

+28.3%

Revenue

$141M

Est $131M

+7.8%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q1 2026Latest	Feb 25, 2026	$0.68vs $0.42+61.9%	$153Mvs $143M+6.8%
Q4 2025	Nov 5, 2025	$0.68vs $0.51+33.3%	$148Mvs $143M+4.0%
Q3 2025	Aug 6, 2025	$0.68vs $0.58+17.2%	$147Mvs $140M+4.4%
Q2 2025	May 7, 2025	$0.68vs $0.53+28.3%	$141Mvs $131M+7.8%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	Debt / Equity
RAREUltragenyx Pharmaceutical Inc.Direct Competitor	2.55B	25.93	-4.45	20.13%	-91.03%	-6.08%
FOLDAmicus Therapeutics, Inc.Direct Competitor	4.47B	14.49	-80.50	32.29%	-2.35%	-6.1%	2.29
ACADACADIA Pharmaceuticals Inc.Direct Competitor	3.68B	21.48	9.38	11.87%	36.49%	41.9%	0.04
PTCTPTC Therapeutics, Inc.Direct Competitor	5.52B	66.61	8.56	114.51%	39.44%
MDGLMadrigal Pharmaceuticals, Inc.Direct Competitor	12.38B	539.73	-42.00	432.05%	-27.32%	-50.15%	0.59
PRAXPraxis Precision Medicines, Inc.Direct Competitor	7.61B	337.95	-25.07	-100%		-58.74%	0.00
ALKSAlkermes plcProduct Competitor	5.89B	35.32	24.70	-5.25%	9.78%	8.82%	0.04
SUPNSupernus Pharmaceuticals, Inc.Product Competitor	2.96B	51.45	-75.66	8.63%	-3.74%	-2.73%	0.04

Compare CPRX vs Peers

Catalyst Pharmaceuticals, Inc. (CPRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs RARE

Most directly comparable listed peer for CPRX.

Scale Benchmark

vs IQV

Larger-name benchmark to compare CPRX against a more recognizable public peer.

Peer Set

Compare Top 5

vs RARE, FOLD, ACAD, PTCT

CPRX Income Statement

Catalyst Pharmaceuticals, Inc. (CPRX) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Sales/Revenue	0	500K	102.31M	119.07M	140.83M	214.2M	398.2M	491.73M	588.99M
Revenue Growth %	-	-	20361.2%	16.39%	18.27%	52.1%	85.9%	23.49%	19.78%
Cost of Goods Sold	45.69K	19.92M	14.76M	17.04M	21.88M	34.39M	51.97M	68.84M	87.25M
COGS % of Revenue	-	3983.84%	14.43%	14.31%	15.54%	16.06%	13.05%	14%	14.81%
Gross Profit	-45.69K▲ 0%	-19.42M▼ 42403.0%	87.55M▲ 550.8%	102.03M▲ 16.5%	118.95M▲ 16.6%	179.81M▲ 51.2%	346.24M▲ 92.6%	422.89M▲ 22.1%	501.74M▲ 18.6%
Gross Margin %	-	-3883.84%	85.57%	85.69%	84.46%	83.94%	86.95%	86%	85.19%
Gross Profit Growth %	-5.26%	-42403.02%	550.83%	16.55%	16.58%	51.17%	92.56%	22.14%	18.64%
Operating Expenses	18.68M	35.8M	55.72M	60.73M	66.56M	77.97M	259.43M	227.76M	243.96M
OpEx % of Revenue	-	7159.03%	54.47%	51%	47.26%	36.4%	65.15%	46.32%	41.42%
Selling, General & Admin	7.3M	15.88M	36.88M	44.23M	49.63M	57.09M	133.71M	177.74M	193.75M
SG&A % of Revenue	-	3175.19%	36.05%	37.15%	35.24%	26.65%	33.58%	36.15%	32.9%
Research & Development	11.38M	19.92M	18.84M	16.5M	16.94M	19.79M	93.15M	12.65M	12.71M
R&D % of Revenue	-	3983.84%	18.42%	13.85%	12.03%	9.24%	23.39%	2.57%	2.16%
Other Operating Expenses	0	1.29M	0	0	0	1.1M	32.56M	37.38M	37.5M
Operating Income	-18.68M▲ 0%	-35.3M▼ 88.9%	31.82M▲ 190.2%	41.3M▲ 29.8%	52.38M▲ 26.8%	101.84M▲ 94.4%	86.81M▼ 14.8%	195.12M▲ 124.8%	257.78M▲ 32.1%
Operating Margin %	-	-7059.03%	31.11%	34.69%	37.2%	47.54%	21.8%	39.68%	43.77%
Operating Income Growth %	3.11%	-88.95%	190.16%	29.79%	26.83%	94.4%	-14.75%	124.77%	32.11%
EBITDA	-18.63M	-35.26M	31.88M	41.4M	52.58M	103.08M	119.69M	232.9M	295.28M
EBITDA Margin %	-	-7051.44%	31.16%	34.76%	37.33%	48.12%	30.06%	47.36%	50.13%
EBITDA Growth %	3.13%	-89.21%	190.42%	29.85%	27.01%	96.05%	16.12%	94.58%	26.78%
D&A (Non-Cash Add-back)	45.69K	37.98K	55K	92K	192K	1.24M	32.88M	37.77M	37.5M
EBIT	-18.41M	-35.3M	31.82M	41.3M	52.38M	101.84M	86.81M	195.12M	257.78M
Net Interest Income	0	1.29M	1.59M	0	0	0	0	16.06M	0
Interest Income	454.16K	1.29M	1.59M	0	0	0	0	16.06M	0
Interest Expense	454.16K	0	0	0	0	0	0	0	0
Other Income/Expense	267.26K	1.29M	1.59M	587K	282K	2.88M	7.7M	21.14M	25.74M
Pretax Income	-18.41M▲ 0%	-34M▼ 84.7%	33.41M▲ 198.3%	41.89M▲ 25.4%	52.67M▲ 25.7%	104.72M▲ 98.8%	94.51M▼ 9.7%	216.26M▲ 128.8%	283.51M▲ 31.1%
Pretax Margin %	-	-6800.7%	32.66%	35.18%	37.4%	48.89%	23.73%	43.98%	48.14%
Income Tax	141.22K	0	1.53M	-33.09M	13.19M	21.64M	23.1M	52.37M	69.19M
Effective Tax Rate %	-0.77%	0%	4.59%	-79%	25.03%	20.66%	24.44%	24.22%	24.4%
Net Income	-18.41M▲ 0%	-34M▼ 84.7%	31.88M▲ 193.7%	74.98M▲ 135.2%	39.48M▼ 47.3%	83.08M▲ 110.4%	71.41M▼ 14.0%	163.89M▲ 129.5%	214.33M▲ 30.8%
Net Margin %	-	-6800.7%	31.16%	62.97%	28.03%	38.79%	17.93%	33.33%	36.39%
Net Income Growth %	-1.88%	-84.68%	193.74%	135.24%	-47.35%	110.42%	-14.05%	129.5%	30.78%
Net Income (Continuing)	-18.41M	-34M	31.88M	74.98M	39.48M	83.08M	71.41M	163.89M	214.33M
Discontinued Operations	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0
EPS (Diluted)	-0.21▲ 0%	-0.33▼ 57.1%	0.30▲ 190.9%	0.71▲ 136.7%	0.37▼ 47.9%	0.75▲ 102.7%	0.63▼ 16.0%	1.31▲ 107.9%	1.68▲ 28.2%
EPS Growth %	4.55%	-57.14%	190.91%	136.67%	-47.89%	102.7%	-16%	107.94%	28.24%
EPS (Basic)	-0.21	-0.33	0.31	0.72	0.38	0.80	0.67	1.38	1.75
Diluted Shares Outstanding	85.8M	102.63M	106.02M	106.24M	107.8M	111.38M	113.75M	124.94M	127.26M
Basic Shares Outstanding	85.8M	102.63M	102.94M	103.51M	103.38M	103.37M	106.28M	118.46M	122.29M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

CPRX Balance Sheet

Catalyst Pharmaceuticals, Inc. (CPRX) balance sheet — assets, liabilities & shareholders' equity

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Total Current Assets	85.19M	55.19M	111.36M	159.24M	210.11M	320.81M	219.33M	623.61M	894.03M
Cash & Short-Term Investments	84.01M	53.48M	94.52M	140.28M	191.27M	298.39M	137.64M	517.55M	709.17M
Cash Only	57.5M	16.56M	89.51M	130.24M	171.44M	298.39M	137.64M	517.55M	709.17M
Short-Term Investments	26.52M	36.92M	5.01M	10.04M	19.82M	0	0	0	0
Accounts Receivable	0	0	10.54M	5.99M	6.72M	10.79M	53.51M	65.49M	126.48M
Days Sales Outstanding	-	-	37.59	18.35	17.43	18.39	49.05	48.61	78.38
Inventory	0	56.01K	1.96M	4.65M	7.87M	6.8M	15.64M	19.54M	37.17M
Days Inventory Outstanding	-	1.03	48.39	99.63	131.26	72.22	109.88	103.6	155.47
Other Current Assets	58.28K	272.17K	516.66K	883K	327K	0	489K	1.03M	21.22M
Total Non-Current Assets	200.27K	5.26M	1.01M	33.11M	27.68M	54.82M	250.78M	227.8M	209.95M
Property, Plant & Equipment	191.38K	245.43K	1M	130K	3.98M	3.62M	3.7M	3.58M	2.97M
Fixed Asset Turnover	-	2.04x	101.93x	915.95x	35.42x	59.22x	107.54x	137.20x	198.18x
Goodwill	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	32.47M	194.05M	156.67M	131.67M
Long-Term Investments	0	5.01M	0	0	0	0	16.49M	21.56M	22.54M
Other Non-Current Assets	8.89K	8.89K	8.89K	9K	9K	0	0	0	0
Total Assets	85.39M▲ 0%	60.45M▼ 29.2%	112.38M▲ 85.9%	192.35M▲ 71.2%	237.79M▲ 23.6%	375.63M▲ 58.0%	470.11M▲ 25.2%	851.41M▲ 81.1%	1.1B▲ 29.7%
Asset Turnover	-	0.01x	0.91x	0.62x	0.59x	0.57x	0.85x	0.58x	0.53x
Asset Growth %	104.73%	-29.21%	85.9%	71.17%	23.62%	57.97%	25.15%	81.11%	29.66%
Total Current Liabilities	4.27M	9.51M	24.1M	22.76M	27.06M	57.59M	76.06M	120.68M	147.15M
Accounts Payable	1.95M	2.34M	4.12M	4.26M	2.77M	3.98M	14.79M	16.59M	11.2M
Days Payables Outstanding	15.54K	42.83	101.83	91.17	46.17	42.19	103.92	87.97	46.86
Short-Term Debt	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	24.01K	0	0	0	0	0	0	0	0
Other Current Liabilities	1.5M	2.04M	3.24M	4.1M	4.28M	5.37M	51.29M	11.16M	135.95M
Current Ratio	19.97x	5.80x	4.62x	7.00x	7.76x	5.57x	2.88x	5.17x	6.08x
Quick Ratio	19.97x	5.80x	4.54x	6.79x	7.47x	5.45x	2.68x	5.01x	5.82x
Cash Conversion Cycle	-	-	-15.84	26.81	102.52	48.42	55.01	64.24	186.99
Total Non-Current Liabilities	157.46K	154.8K	647.53K	0	3.89M	17.62M	6.17M	3.1M	2.56M
Long-Term Debt	0	0	0	0	0	0	0	0	2.35M
Capital Lease Obligations	0	0	647.53K	0	3.89M	3.56M	3.19M	2.79M	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	157.46K	154.8K	0	0	0	14.06M	2.98M	315K	209K
Total Liabilities	4.42M	9.67M	24.75M	22.76M	30.96M	75.21M	82.23M	123.78M	149.71M
Total Debt	0	0	948.05K	29K	4.2M	3.89M	3.56M	3.19M	2.35M
Net Debt	-57.5M	-16.56M	-88.56M	-130.21M	-167.24M	-294.5M	-134.08M	-514.37M	-706.82M
Debt / Equity	-	-	0.01x	0.00x	0.02x	0.01x	0.01x	0.00x	0.00x
Debt / EBITDA	-	-	0.03x	0.00x	0.08x	0.04x	0.03x	0.01x	0.01x
Net Debt / EBITDA	-	-	-2.78x	-3.15x	-3.18x	-2.86x	-1.12x	-2.21x	-2.39x
Interest Coverage	-41.13x	-	-	-	-	-	-	-	-
Total Equity	80.96M▲ 0%	50.78M▼ 37.3%	87.63M▲ 72.6%	169.6M▲ 93.5%	206.83M▲ 22.0%	300.42M▲ 45.2%	387.88M▲ 29.1%	727.63M▲ 87.6%	954.27M▲ 31.1%
Equity Growth %	105.97%	-37.28%	72.55%	93.54%	21.95%	45.25%	29.11%	87.59%	31.15%
Book Value per Share	0.94	0.49	0.83	1.60	1.92	2.70	3.41	5.82	7.50
Total Shareholders' Equity	80.96M	50.78M	87.63M	169.6M	206.83M	300.42M	387.88M	727.63M	954.27M
Common Stock	102.55K	102.74K	103.4K	104K	103K	105K	107K	121K	123K
Retained Earnings	-126.56M	-160.56M	-128.69M	-53.7M	-26.31M	49.86M	121.27M	285.16M	474.19M
Treasury Stock	0	0	0	0	0	0	0	0	0
Accumulated OCI	-159.17K	-20.25K	9.51K	31K	-148K	24K	14K	64K	0
Minority Interest	0	0	0	0	0	0	0	0	0

CPRX Cash Flow Statement

Catalyst Pharmaceuticals, Inc. (CPRX) cash flow — operating, investing & free cash flow history

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Cash from Operations	-13.74M	-25.7M	34.61M	45.03M	60.37M	116.05M	143.6M	239.81M	208.67M
Operating CF Margin %	-	-5140.88%	33.83%	37.82%	42.87%	54.18%	36.06%	48.77%	35.43%
Operating CF Growth %	23.5%	-87.04%	234.65%	30.12%	34.06%	92.22%	23.74%	67%	-12.98%
Net Income	-18.41M	-34M	31.88M	74.98M	39.48M	83.08M	71.41M	163.89M	214.33M
Depreciation & Amortization	45.69K	37.98K	297.73K	885.32K	192K	1.24M	32.88M	37.77M	37.87M
Stock-Based Compensation	2.41M	3.55M	0	0	6.07M	7.91M	14.25M	22.25M	24.78M
Deferred Taxes	0	0	0	-32.97M	9.32M	4.94M	-17.82M	-9.39M	-6.85M
Other Non-Cash Items	186.9K	3.68M	3.53M	6.25M	287K	5.16M	80.2M	-5.63M	-61.46M
Working Capital Changes	2.03M	4.71M	-1.1M	-4.11M	5.02M	13.73M	-37.32M	30.91M	0
Change in Receivables	0	0	-10.54M	4.55M	-632K	-3.82M	-43.08M	-11.96M	-61M
Change in Inventory	0	-56.01K	-1.9M	-2.69M	-3.22M	1.06M	-4.74M	-3.9M	464K
Change in Payables	1.01M	391.79K	1.78M	138.57K	-1.49M	1.21M	10.82M	1.8M	-5.39M
Cash from Investing	-3.96K	-15.53M	37.22M	-5.01M	-11.02M	9.21M	-293.5M	-556K	-58K
Capital Expenditures	0	-92.02K	-19.37K	-11.4K	-1.02M	-29K	-231K	-556K	-58K
CapEx % of Revenue	-	18.4%	0.02%	0.01%	0.73%	0.01%	0.06%	0.11%	0.01%
Acquisitions	0	0	0	0	0	10M	0	0	0
Investments	-	-	-	-	-	-	-	-	-
Other Investing	-3.96K	-14.99M	0	0	0	-10M	-279.81M	0	0
Cash from Financing	57.35M	293.12K	1.12M	701.93K	-8.14M	1.69M	-10.86M	140.66M	-16.99M
Debt Issued (Net)	0	0	0	0	0	0	0	0	0
Equity Issued (Net)	1000K	0	1000K	758.13K	-1000K	-1000K	0	1000K	0
Dividends Paid	0	0	0	0	0	0	0	0	0
Share Repurchases	0	-4.45K	0	0	-12.09M	-6.91M	0	-296K	-25.3M
Other Financing	3.58M	293.12K	0	-56.2K	3.95M	8.6M	-10.86M	-39K	-16.99M
Net Change in Cash	43.6M▲ 0%	-40.94M▼ 193.9%	72.95M▲ 278.2%	40.73M▼ 44.2%	41.21M▲ 1.2%	126.95M▲ 208.1%	-160.76M▼ 226.6%	379.92M▲ 336.3%	191.62M▼ 49.6%
Free Cash Flow	-13.74M▲ 0%	-25.8M▼ 87.7%	34.59M▲ 234.1%	45.02M▲ 30.2%	59.35M▲ 31.8%	116.02M▲ 95.5%	61.86M▼ 46.7%	239.25M▲ 286.8%	208.61M▼ 12.8%
FCF Margin %	-	-5159.28%	33.81%	37.81%	42.14%	54.16%	15.53%	48.65%	35.42%
FCF Growth %	23.9%	-87.71%	234.1%	30.16%	31.82%	95.48%	-46.68%	286.79%	-12.81%
FCF per Share	-0.16	-0.25	0.33	0.42	0.55	1.04	0.54	1.91	1.64
FCF Conversion (FCF/Net Income)	0.75x	0.76x	1.09x	0.60x	1.53x	1.40x	2.01x	1.46x	0.97x
Interest Paid	0	0	0	0	0	0	705K	1.4M	0
Taxes Paid	0	0	0	0	3M	7.67M	50.46M	68.45M	0

CPRX Key Ratios

Catalyst Pharmaceuticals, Inc. (CPRX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-38.13%	-30.62%	-51.62%	46.06%	58.3%	20.98%	32.76%	20.75%	29.38%	25.49%
Return on Invested Capital (ROIC)	-54.92%	-57.32%	-91.77%	143.39%	161.1%	99.49%	335.67%	50.14%	62.66%	83.93%
Gross Margin	-	-	-3883.84%	85.57%	85.69%	84.46%	83.94%	86.95%	86%	85.19%
Net Margin	-	-	-6800.7%	31.16%	62.97%	28.03%	38.79%	17.93%	33.33%	36.39%
Debt / Equity	-	-	-	0.01x	0.00x	0.02x	0.01x	0.01x	0.00x	0.00x
Interest Coverage	-59.95x	-41.13x	-	-	-	-	-	-	-	-
FCF Conversion	0.99x	0.75x	0.76x	1.09x	0.60x	1.53x	1.40x	2.01x	1.46x	0.97x
Revenue Growth	-	-	-	20361.2%	16.39%	18.27%	52.1%	85.9%	23.49%	19.78%

CPRX SEC Filings & Documents

Catalyst Pharmaceuticals, Inc. (CPRX) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

Mar 18, 2026·SEC

Material company update

Feb 25, 2026·SEC

Material company update

Jan 12, 2026·SEC

10-K Annual Reports

FY 2026

Feb 25, 2026·SEC

FY 2025

Feb 26, 2025·SEC

FY 2024

Feb 28, 2024·SEC

10-Q Quarterly Reports

FY 2025

Nov 5, 2025·SEC

FY 2025

Aug 6, 2025·SEC

FY 2025

May 7, 2025·SEC

CPRX Frequently Asked Questions

Catalyst Pharmaceuticals, Inc. (CPRX) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Catalyst Pharmaceuticals, Inc. (CPRX) reported $589.0M in revenue for fiscal year 2025.

Catalyst Pharmaceuticals, Inc. (CPRX) grew revenue by 19.8% over the past year. This is strong growth.

Yes, Catalyst Pharmaceuticals, Inc. (CPRX) is profitable, generating $214.3M in net income for fiscal year 2025 (36.4% net margin).

Dividend & Returns

Catalyst Pharmaceuticals, Inc. (CPRX) has a return on equity (ROE) of 25.5%. This is excellent, indicating efficient use of shareholder capital.

Catalyst Pharmaceuticals, Inc. (CPRX) generated $208.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More CPRX

Catalyst Pharmaceuticals, Inc. (CPRX) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

Catalyst Pharmaceuticals, Inc.(CPRX)Earnings, Financials & Key Ratios

CPRX Key Insights

✓Strengths

✗Weaknesses

CPRX Price & Volume

CPRX Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

CPRX Recent Earnings

CPRX Peer Comparison

Compare CPRX vs Peers

vs RARE

vs IQV

Compare Top 5

CPRX Income Statement

CPRX Balance Sheet

CPRX Cash Flow Statement

CPRX Key Ratios

CPRX SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

CPRX Frequently Asked Questions

Explore More CPRX

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation